(MENAFN- America News Hour) The trachoma treatment market is expected to register a CAGR of 5.5% during the forecast period. This is attributed to the increasing prevalence of trachoma due to the rising air pollution, and the lack of maintenance of personal hygiene by majority of people in underdeveloped countries.
– Trachoma is an infectious eye disease, which is caused by bacterium chlamydia trachomatis, and as per the World Health Organization (WHO), it is the leading cause of blindness and one of 20 neglected tropical diseases that affects one billion of the world's poorest people.
– Moreover, poor sanitation, such as sharing the used towels and clothes and unhygienic water and food consumption, may propel the studied market's growth in underdeveloped countries. In addition, as per the World Health Organization (2018), globally, an estimated 89.1 million people had been treated with antibiotics for eliminating trachoma, which further boost the revenue growth of the market studied.
Get a Sample Copy of this Report with Graphs and Charts:
Key Market Trends
Oral Route of Administration is Dominating the Market
The oral route of administration segment is expected to hold a largest market share, owing to easy mode of administration with most favored, ease of production, cost effectiveness, flexibility in design of dosage forms, and least sterility constraints. As antibiotics are the first line of therapy for the targeted patient pool, it may boost the revenue growth of the segment. Antibiotics, such as azithromycin and tetracycline, are the most commonly used for the treatment of trachoma.
Middle East & Africa is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
The Middle East & Africa is expected to hold a significant market share in the global trachoma treatment market, as it is the most affected region with trachoma cases. As per the World Health Organization (WHO), in 2016, an estimated 247,000 people being treated with surgical treatment for trichiasis, and 83 million people were treated with antibiotic therapy. In addition, 142 million people live in trachoma endemic areas and are at risk of trachoma blindness, which further propels the revenue growth of this region.
Download Sample PDF of this Report: –
Competitive Landscape
The market studied is moderately competitive, and there are several international as well as local companies. Some of the companies that are currently dominating the market are Allergan, Apotex, Pfizer Inc., Teva Pharmaceutical Industries Ltd, Sandoz Inc. (Novartis AG), Arbor Pharmaceuticals Inc., Fresenius Kabi AG, Merck & Co. Inc., and AbbVie Inc., among others.
1 INTRODUCTION
1.1 Study Assumptions
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Incidence and Prevalence of Trachoma
4.2.2 Favourable Government Initiative
4.3 Market Restraints
4.3.1 Lack of Awareness
4.3.2 Side Effects
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
Ask for it and browse full report- trachoma treatment market
About SDKI:
The dynamic nature of business environment in the current global economy is raising the need amongst business professionals to update themselves with current situations in the market. To cater such needs, Shibuya Data Count ( SDKI ) provides market research reports to various business professionals across different industry verticals, such as healthcare & pharmaceutical, IT & telecom, chemicals and advanced materials, consumer goods & food, energy & power, manufacturing & construction, industrial automation & equipment and agriculture & allied activities amongst others.